Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 18

Showing 18 citing articles:

Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
Alberto J. Espay, Fabrizio Stocchi, Rajesh Pahwa, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 5, pp. 465-476
Closed Access | Times Cited: 29
A Comprehensive Approach to Parkinson’s Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects
Mauricio Muleiro Álvarez, Gabriela Cano-Herrera, María Fernanda Osorio Martínez, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7183-7183
Open Access | Times Cited: 16
Subcutaneous Levodopa: A New Engine for the Vintage Molecule
Karolina Popławska-Domaszewicz, Lucia Batzu, Cristian Falup‐Pecurariu, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 4, pp. 1055-1068
Open Access | Times Cited: 7
Parkinson’s disease therapy: what lies ahead?
Andreas Wolff, Nicolas U Schumacher, Dominik Pürner, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 793-820
Open Access | Times Cited: 15
Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
Manon Auffret, Daniel Weiß, Fabrizio Stocchi, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1411-1432
Open Access | Times Cited: 13
Current and novel infusion therapies for patients with Parkinson's disease
Angelo Antonini, Valentina D’Onofrio, Andrea Guerra
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1349-1358
Open Access | Times Cited: 12
The role of istradefylline in the Parkinson’s disease armamentarium
Thomas Müller
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 7, pp. 863-871
Closed Access | Times Cited: 11
Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Peter Riederer, Sabrina Strobel, Toshiharu Nagatsu, et al.
Journal of Neural Transmission (2025)
Open Access
Efficacy and Safety of Novel Continuous Subcutaneous Levodopa Infusion Therapies ND0612 and ABBV-951 for Parkinson’s Disease: A Systematic Review
Matheus Augusto Mesquita Fernandes, Luis O. S. Nogueira, Isabella Soares Marques Rabelo, et al.
Journal of Geriatric Psychiatry and Neurology (2025)
Closed Access
Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants
Gian Pal, Daniel M. Corcos, Leo Verhagen Metman, et al.
Movement Disorders (2023) Vol. 38, Iss. 12, pp. 2155-2162
Open Access | Times Cited: 10
Fluctuations in Parkinson's disease: progress and challenges
Francisco Cardoso, Eduardo Tolosa
The Lancet Neurology (2024) Vol. 23, Iss. 5, pp. 448-449
Closed Access | Times Cited: 3
Levodopa infusion therapies for Parkinson disease
Marissa Dean, David G. Standaert
Current Opinion in Neurology (2024) Vol. 37, Iss. 4, pp. 409-413
Closed Access | Times Cited: 3
Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
Phoebe Tall, Mubasher A. Qamar, Lucia Batzu, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1443-1449
Open Access | Times Cited: 6
Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion
Filip Bergquist, M. Ehrnebo, Dag Nyholm, et al.
Movement Disorders Clinical Practice (2024) Vol. 11, Iss. 9, pp. 1095-1102
Open Access | Times Cited: 1
Therapeutic drug monitoring in Parkinson’s disease
Thomas Müller, Manfred Gerlach, Gudrun Hefner, et al.
Journal of Neural Transmission (2024)
Closed Access | Times Cited: 1
Liquid Subcutaneous Levodopa-Carbidopa ND0612 Effects on Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis
Paula Abola, Mitch Wolden, Kristin Lefebvre
Advances in Parkinson s Disease (2024) Vol. 13, Iss. 02, pp. 9-25
Open Access
Clinicians’ viewpoints on current paradigms of care and research in Parkinson’s disease
Thomas Müller, Carsten Buhmann, Martin Delf, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 12, pp. 1455-1462
Closed Access
Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson’s disease: is it an improvement on other delivery?
Sheila A Doggrell
Expert Opinion on Drug Delivery (2023) Vol. 20, Iss. 9, pp. 1189-1199
Closed Access | Times Cited: 1
Page 1

Scroll to top